Description: 4DMT is a clinical-stage gene therapy company pioneering the development of product candidates using targeted and evolved AAV vectors. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP, 4D-110 is in a Phase 1 clinical trial for choroideremia and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease.
Home Page: www.4dmoleculartherapeutics.com
FDMT Technical Analysis
5858 Horton Street
EmeryVille,
CA
94608
United States
Phone:
510 505 2680
Officers
| Name | Title |
|---|---|
| Dr. John F. Milligan Ph.D. | Exec. Chairman |
| Dr. David H. Kirn M.D. | Co-Founder, CEO & Director |
| Ms. Theresa Janke | Co-Founder & Chief of Staff |
| Mr. August J. Moretti Esq., J.D. | Chief Financial Officer |
| Dr. Fred Kamal Ph.D. | Pres & COO |
| Mike Zanoni | VP of Investor Relations |
| Dr. Scott P. Bizily J.D., Ph.D. | Chief Legal & HR Officer and Corp. Sec. |
| Dr. Robert S. Fishman | Chief Medical Officer & Therapeutic Area Head of Pulmonology |
| Dr. Raphael Schiffmann M.D. | Sr. VP & Therapeutic Area Head of Cardiology |
| Dr. Robert Y. Kim M.B.A., M.D. | Sr. VP & Clinical Therapeutic Area Head of Ophthalmology |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.0145 |
| Price-to-Sales TTM: | 378.8959 |
| IPO Date: | 2020-12-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 140 |